Estimates of Screening Benefit

The Randomized Trials of Breast Cancer Screening

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The benefits of mammography screening have been studied in nine randomized controlled trials comparing women randomized to screening or nonscreening groups. Randomized controlled trials are regarded as the strongest study design to determine effectiveness because they are less susceptible to bias than other study designs. The trials began between 1965 and 1991, and involved over 600,000 women in the United States, Canada, United Kingdom, and Sweden. The trials varied in their recruitment of women, the number of women enrolled, and randomization. Major limitations include comparability of screening and nonscreening groups, clinical relevance to current populations and practice, and whether the effects of screening in trials differ from the general population. Results indicate reduced breast cancer mortality with screening that varies by age. Results for ages 40-49 and 50-59 years are of borderline statistical significance and vary by how cases were accrued in trials; estimates for age 70-74 years are limited by the small number of trial participants. All-cause mortality was not reduced with screening, while advanced breast cancer was reduced for women age 50 and older, but not younger women.

Original languageEnglish (US)
Title of host publicationBreast Cancer Screening: An Examination of Scientific Evidence
PublisherElsevier Inc.
Pages29-49
Number of pages21
ISBN (Print)9780128024942, 9780128022092
DOIs
StatePublished - Apr 5 2016

Fingerprint

Early Detection of Cancer
Breast Neoplasms
Randomized Controlled Trials
Mortality
Mammography
Random Allocation
Sweden
Population
Canada

Keywords

  • Breast cancer
  • Mammography
  • Randomized controlled trials
  • Screening

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Estimates of Screening Benefit : The Randomized Trials of Breast Cancer Screening. / Nelson, Heidi; Humphrey, Linda; Fu, Rongwei (Rochelle).

Breast Cancer Screening: An Examination of Scientific Evidence. Elsevier Inc., 2016. p. 29-49.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nelson, Heidi ; Humphrey, Linda ; Fu, Rongwei (Rochelle). / Estimates of Screening Benefit : The Randomized Trials of Breast Cancer Screening. Breast Cancer Screening: An Examination of Scientific Evidence. Elsevier Inc., 2016. pp. 29-49
@inbook{deb4e542c312407fa0d9b38c6e9077cb,
title = "Estimates of Screening Benefit: The Randomized Trials of Breast Cancer Screening",
abstract = "The benefits of mammography screening have been studied in nine randomized controlled trials comparing women randomized to screening or nonscreening groups. Randomized controlled trials are regarded as the strongest study design to determine effectiveness because they are less susceptible to bias than other study designs. The trials began between 1965 and 1991, and involved over 600,000 women in the United States, Canada, United Kingdom, and Sweden. The trials varied in their recruitment of women, the number of women enrolled, and randomization. Major limitations include comparability of screening and nonscreening groups, clinical relevance to current populations and practice, and whether the effects of screening in trials differ from the general population. Results indicate reduced breast cancer mortality with screening that varies by age. Results for ages 40-49 and 50-59 years are of borderline statistical significance and vary by how cases were accrued in trials; estimates for age 70-74 years are limited by the small number of trial participants. All-cause mortality was not reduced with screening, while advanced breast cancer was reduced for women age 50 and older, but not younger women.",
keywords = "Breast cancer, Mammography, Randomized controlled trials, Screening",
author = "Heidi Nelson and Linda Humphrey and Fu, {Rongwei (Rochelle)}",
year = "2016",
month = "4",
day = "5",
doi = "10.1016/B978-0-12-802209-2.00002-4",
language = "English (US)",
isbn = "9780128024942",
pages = "29--49",
booktitle = "Breast Cancer Screening: An Examination of Scientific Evidence",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Estimates of Screening Benefit

T2 - The Randomized Trials of Breast Cancer Screening

AU - Nelson, Heidi

AU - Humphrey, Linda

AU - Fu, Rongwei (Rochelle)

PY - 2016/4/5

Y1 - 2016/4/5

N2 - The benefits of mammography screening have been studied in nine randomized controlled trials comparing women randomized to screening or nonscreening groups. Randomized controlled trials are regarded as the strongest study design to determine effectiveness because they are less susceptible to bias than other study designs. The trials began between 1965 and 1991, and involved over 600,000 women in the United States, Canada, United Kingdom, and Sweden. The trials varied in their recruitment of women, the number of women enrolled, and randomization. Major limitations include comparability of screening and nonscreening groups, clinical relevance to current populations and practice, and whether the effects of screening in trials differ from the general population. Results indicate reduced breast cancer mortality with screening that varies by age. Results for ages 40-49 and 50-59 years are of borderline statistical significance and vary by how cases were accrued in trials; estimates for age 70-74 years are limited by the small number of trial participants. All-cause mortality was not reduced with screening, while advanced breast cancer was reduced for women age 50 and older, but not younger women.

AB - The benefits of mammography screening have been studied in nine randomized controlled trials comparing women randomized to screening or nonscreening groups. Randomized controlled trials are regarded as the strongest study design to determine effectiveness because they are less susceptible to bias than other study designs. The trials began between 1965 and 1991, and involved over 600,000 women in the United States, Canada, United Kingdom, and Sweden. The trials varied in their recruitment of women, the number of women enrolled, and randomization. Major limitations include comparability of screening and nonscreening groups, clinical relevance to current populations and practice, and whether the effects of screening in trials differ from the general population. Results indicate reduced breast cancer mortality with screening that varies by age. Results for ages 40-49 and 50-59 years are of borderline statistical significance and vary by how cases were accrued in trials; estimates for age 70-74 years are limited by the small number of trial participants. All-cause mortality was not reduced with screening, while advanced breast cancer was reduced for women age 50 and older, but not younger women.

KW - Breast cancer

KW - Mammography

KW - Randomized controlled trials

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84969592244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969592244&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802209-2.00002-4

DO - 10.1016/B978-0-12-802209-2.00002-4

M3 - Chapter

SN - 9780128024942

SN - 9780128022092

SP - 29

EP - 49

BT - Breast Cancer Screening: An Examination of Scientific Evidence

PB - Elsevier Inc.

ER -